A61K 40/45
Bacterial antigens
A61K40/45 (Bacterial antigens) appears on 132 US grants and 259 published applications in this corpus.
Search patents in A61K- Granted patents
- 132
- Published applications
- 259
- Assignees
- 158
- Inventors
- 476
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1997 | 1 | 0 |
| 1998 | 2 | 0 |
| 1999 | 2 | 0 |
| 2000 | 1 | 0 |
| 2001 | 3 | 2 |
| 2002 | 3 | 7 |
| 2003 | 1 | 11 |
| 2004 | 1 | 16 |
| 2005 | 1 | 8 |
| 2006 | 2 | 6 |
| 2007 | 1 | 4 |
| 2008 | 6 | 13 |
| 2009 | 2 | 16 |
| 2010 | 4 | 5 |
| 2011 | 9 | 8 |
| 2012 | 7 | 11 |
| 2013 | 6 | 8 |
| 2014 | 3 | 10 |
| 2015 | 7 | 7 |
| 2016 | 3 | 9 |
| 2017 | 4 | 6 |
| 2018 | 7 | 13 |
| 2019 | 3 | 13 |
| 2020 | 5 | 18 |
| 2021 | 10 | 21 |
| 2022 | 8 | 12 |
| 2023 | 9 | 10 |
| 2024 | 8 | 12 |
| 2025 | 8 | 9 |
| 2026 | 5 | 4 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- A61K 40/453Clostridium24
- A61K 40/4524Mycobacterium21
- A61K 40/4532Staphylococcus14
- A61K 40/4568Chlamydiaceae12
- A61K 40/4526Corynebacterium or propionibacterium, actinobacteria5
- A61K 40/4528Bacillus5
- A61K 40/4562Salmonella5
- A61K 40/4512Bacteriodetes3
All 23 subgroupsShow fewer
- A61K 40/4534Streptococcus3
- A61K 40/4544Pseudomonadales3
- A61K 40/456Escherichia2
- A61K 40/4536Lactobacillales1
- A61K 40/4538Neisseria1
- A61K 40/4514Spirochetes0
- A61K 40/4516Rickettsiales0
- A61K 40/4518Mollicutes0
- A61K 40/452Enterobacteriales0
- A61K 40/454Brucella0
- A61K 40/4542Pasteurellales0
- A61K 40/4548Delta proteobacteriales0
- A61K 40/455Vibrio0
- A61K 40/4564Fusobacterium0
- A61K 40/4566Polyvalent bacterial antigens0
Recent patents
- Engineered cells and uses thereof6 Oct 2026US 12,751,929 B2Ohio State Innovation Foundation
- Compositions and methods for increasing T cell function15 Sep 2026US 12,734,150 B2Ludwig Institute for Cancer Research
- Artificial antigen presenting cells comprising protein L for expanding immune cells for immunotherapy30 Jun 2026US 12,668,776 B2H. Lee Moffitt Cancer Center and Research Institute, Inc.
- BCG car constructs and methods of their manufacture and use13 Jan 2026US 12,522,651 B2Versiti Blood Research Institute Foundation, Inc.
- Compositions and methods for treating HIV infection and reversing HIV latency6 Jan 2026US 12,514,921 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Expression of antigen-adjuvant fusion subunit proteins in diatoms, and methods of generation and use thereof16 Jul 2026US 2026/0200994 A1PhycoVax LLC
- Nanoparticles for delivery of immunoregulatory materials to t cells5 Mar 2026US 2026/0061054 A1The Johns Hopkins University
- Bioorthogonal t cell receptor molecules and methods of making and using the same26 Feb 2026US 2026/0055158 A1The University of North Carolina at Chapel Hill
- Generation of functional neutrophils and macrophages from induced pluripotent stem cells in chemically defined conditions using transient expression of etv212 Feb 2026US 2026/0043002 A1
- Artificial antigen presenting cells comprising protein l for expanding immune cells for immunotherapy25 Dec 2025US 2025/0388860 A1H. Lee Moffitt Cancer Center and Research Institute, Inc.
Most cited
By later US patents
- Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens124US 5,994,126 AThe Rockefeller University · 1999
- Mesenchymal stem cells as immunosuppressants110US 6,797,269 B2Osiris Therapeutics, Inc. · 2004
- Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens55US 5,851,756 AThe Rockefeller University · 1998
- Methods of generating antigen-specific CD4+CD25+regulatory T cells, compositions and methods of use55US 8,053,235 B2Benaroya Research Institute at Virginia Mason · 2011
- Activated dendritic cells and methods for their activation54US 6,017,527 AImmunex Corporation · 2000